Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Aptose Biosciences Inc (APTOF)

Aptose Biosciences Inc (APTOF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]

Fundamentals

See More
  • Market Capitalization, $K 3,701
  • Shares Outstanding, K 2,552
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,430 K
  • EBIT $ -19 M
  • EBITDA $ -19 M
  • 60-Month Beta 0.39
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -7.38
  • Most Recent Earnings $-2.01 on 11/13/25
  • Next Earnings Date 03/27/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.4500 unch
on 12/24/25
1.6800 -13.69%
on 12/16/25
-0.1800 (-11.04%)
since 11/24/25
3-Month
1.0801 +34.25%
on 10/03/25
1.7200 -15.70%
on 11/19/25
+0.2400 (+19.83%)
since 09/23/25
52-Week
0.6363 +127.88%
on 06/18/25
8.0850 -82.07%
on 12/26/24
-6.0500 (-80.67%)
since 12/24/24

Most Recent Stories

More News
Aptose Biosciences Announces Rescheduling of Special Meeting of Shareholders to Approve the Acquisition by Hanmi Pending Final Clearance from SEC

SAN DIEGO and TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) announced today that it will be rescheduling its upcoming...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose’s Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML Populations

TUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutations Safety continues to be a notable hallmark...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences Announces Arrangement Agreement for Acquisition by Hanmi Pharmaceutical

SAN DIEGO and TORONTO, Nov. 19, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. (“Hanmi”) today announced...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Reports Third Quarter 2025 Results

Tuspetinib Continues to Demonstrate Excellent Safety and Complete Responses in the TUSCANY Clinical Trial of Tuspetinib in AML Triple Drug Frontline Therapy at Increased Dose Levels Patients are Now...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Tuspetinib Clinical Data from Ongoing TUSCANY Trial in Newly Diagnosed AML Selected for Presentation at the 2025 ASH Annual Meeting

SAN DIEGO and TORONTO, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS), a clinical-stage precision oncology company developing a tuspetinib (TUS)...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose’s Tuspetinib Shows Promising Results in AML Treatment Trial

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Aptose Biosciences...

APTOF : 1.4500 (-3.97%)
Aptose’s Tuspetinib Exceeds Expectations When Combined with Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML

Addition of TUS to VEN+AZA achieves CR/CRh responses in all (6/6, 100%) patients treated at the higher dose levels of 80 mg and 120 mg TUS, exceeding the 66% rate expected from VEN+AZA alone CR/CRh...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose and Hanmi Pharmaceutical Extend Loan Agreement to Continue Development of Tuspetinib in Triplet Therapy for AML

SAN DIEGO and TORONTO, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Biosciences Announces Results of Reconvened Annual and Special Shareholders Meeting and Appointment of Ernst & Young LLP as New Auditor

SAN DIEGO and TORONTO, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (TSX: APS; OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)
Aptose Reports Early Data Demonstrating Tuspetinib Improves Standard of Care Treatment Across Diverse Populations of Newly Diagnosed AML in Phase 1/2 TUSCANY Trial

Addition of Tuspetinib (TUS) to Venetoclax (VEN) and Azacitidine (AZA) is being developed as safe and mutation agnostic frontline therapy for AML Addition of TUS to VEN+AZA improves response rates;...

APTOF : 1.4500 (-3.97%)
APS.TO : 2.01 (-4.29%)

Business Summary

Aptose Biosciences Inc. is a clinical-stage biotechnology company. The company is advancing therapeutics to treat life-threatening cancers, such as acute myeloid leukemia, high-risk myelodysplastic syndromes and other hematologic malignancies. Its lead program APTO-253 has completed a Phase 1 study in...

See More

Key Turning Points

3rd Resistance Point 1.5833
2nd Resistance Point 1.5567
1st Resistance Point 1.5033
Last Price 1.4500
1st Support Level 1.4233
2nd Support Level 1.3967
3rd Support Level 1.3433

See More

52-Week High 8.0850
Fibonacci 61.8% 5.2396
Fibonacci 50% 4.3607
Fibonacci 38.2% 3.4817
Last Price 1.4500
52-Week Low 0.6363

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar